LONGEVERON INC-A (LGVN) Stock Price & Overview
NASDAQ:LGVN • US54303L2034
Current stock price
The current stock price of LGVN is 0.98 USD. Today LGVN is down by -11.71%. In the past month the price increased by 70.41%. In the past year, price decreased by -47.03%.
LGVN Key Statistics
- Market Cap
- 28.694M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.28
- Dividend Yield
- N/A
LGVN Stock Performance
LGVN Stock Chart
LGVN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LGVN. When comparing the yearly performance of all stocks, LGVN is one of the better performing stocks in the market, outperforming 79.98% of all stocks.
LGVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LGVN. LGVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LGVN Earnings
On March 17, 2026 LGVN reported an EPS of -0.22 and a revenue of 370.00K. The company beat EPS expectations (48.03% surprise) and beat revenue expectations (145.1% surprise).
LGVN Forecast & Estimates
8 analysts have analysed LGVN and the average price target is 7 USD. This implies a price increase of 614.26% is expected in the next year compared to the current price of 0.98.
For the next year, analysts expect an EPS growth of -4.79% and a revenue growth -11.83% for LGVN
LGVN Groups
Sector & Classification
LGVN Financial Highlights
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by 69.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.18% | ||
| ROE | -214.14% | ||
| Debt/Equity | 0 |
LGVN Ownership
LGVN Latest News, Press Relases and Analysis
LGVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LGVN
Company Profile
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Company Info
IPO: 2021-02-12
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 25
Phone: 13053027158
LONGEVERON INC-A / LGVN FAQ
What does LONGEVERON INC-A do?
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Can you provide the latest stock price for LONGEVERON INC-A?
The current stock price of LGVN is 0.98 USD. The price decreased by -11.71% in the last trading session.
Does LONGEVERON INC-A pay dividends?
LGVN does not pay a dividend.
How is the ChartMill rating for LONGEVERON INC-A?
LGVN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for LONGEVERON INC-A?
LONGEVERON INC-A (LGVN) currently has 25 employees.
What is the ownership structure of LONGEVERON INC-A (LGVN)?
You can find the ownership structure of LONGEVERON INC-A (LGVN) on the Ownership tab.
What is the outstanding short interest for LONGEVERON INC-A?
The outstanding short interest for LONGEVERON INC-A (LGVN) is 8.47% of its float.